Overview

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPĪ±-CD47 Pathway, in Solid or Hematological Tumors

Status:
Not yet recruiting
Trial end date:
2025-11-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed or refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Phase:
Phase 1
Details
Lead Sponsor:
FBD Biologics Limited